中华放射肿瘤学杂志
中華放射腫瘤學雜誌
중화방사종류학잡지
CHINESE JOURNAL OF RADIATION ONCOLOGY
2013年
3期
217-219
,共3页
张冉%吴君心%徐鹭英%林少俊%杨凌%陈传本%潘建基
張冉%吳君心%徐鷺英%林少俊%楊凌%陳傳本%潘建基
장염%오군심%서로영%림소준%양릉%진전본%반건기
鼻咽肿瘤/调强放射疗法%临床分型
鼻嚥腫瘤/調彊放射療法%臨床分型
비인종류/조강방사요법%림상분형
Nasopharyngeal neoplasms/intensity-modulated radiotherapy%Clinical typing
目的 探讨调强放疗时代鼻咽癌患者临床分型的现状.方法 分析2003-2006年本院连续收治的初治、无远处转移、调强放疗的鼻咽癌333例,根据预后情况进行临床分型.分型定义为Ⅰ型:放射敏感不易转移型；Ⅱ型:放射抗拒不易转移型；Ⅲ型:放射敏感易转移型；Ⅳ型:放射抗拒易转移型.结果 全组Ⅰ、Ⅱ、Ⅲ、Ⅳ型所占比例分别为70.0％(233例)、12.9％(43例)、16.5％(55例)、0.6％(2例)；Ⅰ+Ⅱ期(57例)分别为86％(49例)、11％(6例)、4％(2例)、0％(0例),Ⅲ+Ⅳ期(276例)分别为66.7％(184例)、13.4％(37例)、19.2％(53例)、0.7％(2例)(P=0.007)；无化疗者(69例)分别为80％(55例)、12％(8例)、9％(6例)、0％(0例),新辅助加同期化疗者(218例)分别为68.8％(150例)、13.8％(30例)、16.5％(36例)、0.9％(2例),新辅助加辅助化疗者(46例)分别为61％(28例)、11％(5例)、28％(13例)、0％(0例).结论 Ⅰ型在早、晚期均占最大比例,Ⅳ型均占最小比例；早期中Ⅱ型＞Ⅲ型,晚期中Ⅲ型＞Ⅱ型.与常规放疗资料相比Ⅰ型比例提高,其他型均减少.
目的 探討調彊放療時代鼻嚥癌患者臨床分型的現狀.方法 分析2003-2006年本院連續收治的初治、無遠處轉移、調彊放療的鼻嚥癌333例,根據預後情況進行臨床分型.分型定義為Ⅰ型:放射敏感不易轉移型；Ⅱ型:放射抗拒不易轉移型；Ⅲ型:放射敏感易轉移型；Ⅳ型:放射抗拒易轉移型.結果 全組Ⅰ、Ⅱ、Ⅲ、Ⅳ型所佔比例分彆為70.0％(233例)、12.9％(43例)、16.5％(55例)、0.6％(2例)；Ⅰ+Ⅱ期(57例)分彆為86％(49例)、11％(6例)、4％(2例)、0％(0例),Ⅲ+Ⅳ期(276例)分彆為66.7％(184例)、13.4％(37例)、19.2％(53例)、0.7％(2例)(P=0.007)；無化療者(69例)分彆為80％(55例)、12％(8例)、9％(6例)、0％(0例),新輔助加同期化療者(218例)分彆為68.8％(150例)、13.8％(30例)、16.5％(36例)、0.9％(2例),新輔助加輔助化療者(46例)分彆為61％(28例)、11％(5例)、28％(13例)、0％(0例).結論 Ⅰ型在早、晚期均佔最大比例,Ⅳ型均佔最小比例；早期中Ⅱ型＞Ⅲ型,晚期中Ⅲ型＞Ⅱ型.與常規放療資料相比Ⅰ型比例提高,其他型均減少.
목적 탐토조강방료시대비인암환자림상분형적현상.방법 분석2003-2006년본원련속수치적초치、무원처전이、조강방료적비인암333례,근거예후정황진행림상분형.분형정의위Ⅰ형:방사민감불역전이형；Ⅱ형:방사항거불역전이형；Ⅲ형:방사민감역전이형；Ⅳ형:방사항거역전이형.결과 전조Ⅰ、Ⅱ、Ⅲ、Ⅳ형소점비례분별위70.0％(233례)、12.9％(43례)、16.5％(55례)、0.6％(2례)；Ⅰ+Ⅱ기(57례)분별위86％(49례)、11％(6례)、4％(2례)、0％(0례),Ⅲ+Ⅳ기(276례)분별위66.7％(184례)、13.4％(37례)、19.2％(53례)、0.7％(2례)(P=0.007)；무화료자(69례)분별위80％(55례)、12％(8례)、9％(6례)、0％(0례),신보조가동기화료자(218례)분별위68.8％(150례)、13.8％(30례)、16.5％(36례)、0.9％(2례),신보조가보조화료자(46례)분별위61％(28례)、11％(5례)、28％(13례)、0％(0례).결론 Ⅰ형재조、만기균점최대비례,Ⅳ형균점최소비례；조기중Ⅱ형＞Ⅲ형,만기중Ⅲ형＞Ⅱ형.여상규방료자료상비Ⅰ형비례제고,기타형균감소.
Objective To investigate the clinical typing of nasopharyngeal carcinoma in patients treated by intensity-modulated radiation therapy (IMRT).Methods A retrospective analysis was performed on 333 patients with nasopharyngeal carcinoma who were initially treated in our hospital from 2003 to 2006 ;they had no distant metastasis and received IMRT.These patients were divided into 4 clinical types according to their prognosis:type Ⅰ (without local-regional recurrence and without distant metastasis),type Ⅱ (with local-regional recurrence and without distant metastasis),type Ⅲ (without local-regional recurrence and with distant metastasis),and type Ⅳ (with local-regional recurrence and with distant metastasis).Results Of all the patients,70.0％ (233) were of type Ⅰ,12.9％ (43) of type Ⅱ,16.5％ (55) of type Ⅲ,and 0.6％ (2) of type Ⅳ.Of 57 patients with stage Ⅰ-Ⅱ nasophayngeal carcinoma,86％ (49) were of type Ⅰ,11％ (6) of type Ⅱ,4％ (2) of type Ⅲ,and 0％ (0) of type Ⅳ,and of 276 patients with stage Ⅲ-Ⅳ nasopharyngeal carcinoma,66.7％ (184) were of type Ⅰ,13.4％ (37) of type Ⅱ,19.2％ (53) of type Ⅲ,and 0.7％ (2) of type Ⅳ,with significant differences between the two patient groups (P =0.007).Of the 69 patients who received IMRT alone,80％ (55) were of type Ⅰ,12％ (8) of type Ⅱ,9％(6) of type Ⅲ,and 0％ (0) of type Ⅳ; of the 218 patients who received IMRT combined with neoadjuvant plus concurrent chemotherapy,68.8％ (150) were of type Ⅰ,13.8％ (30) of type Ⅱ,16.5％(36) of type Ⅲ,and 0.9％ (2) of type Ⅳ; of the 46 patients who received IMRT combined with neoadjuvant plus adjuvant chemotherapy,61％ (28) were of type Ⅰ,11％ (5) of type Ⅱ,28％ (13) of type Ⅲ,and 0％ (0) of type Ⅳ.Conclusions In patients with early and advanced nasopharyngeal carcinoma,type Ⅰ is the most common,and type Ⅳ is the least common;type Ⅱ is more frequent than type Ⅲ in early patients,while type Ⅲ is more frequent than type Ⅱ in advanced patients.The percentage of type Ⅰ patients increases,while that of type Ⅱ-Ⅳ patients decreases,as compared with the data of those treated by conventional radiotherapy.
